ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using our proprietary drug delivery technologies, primarily in the area of pain management. ZARS has two approved products and many more in various stages of development. Synera® (lidocaine 70mg/tetracaine 70mg topical patch) is a topical patch designed to provide local dermal anesthesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Synera uses our CHADD® technology and a proprietary local anesthetic formulation that contains lidocaine and tetracaine. We are commercializing Synera in the United States and our partner, EuroCept, markets Synera (named Rapydan) in Europe. Synera resembles a small adhesive bandage in appearance and is applied to the skin before painful medical procedures such as venous access, blood draws, needle injections and minor dermatologic surgical procedures. Synera is applied for 20 to 30 minutes prior to venous access procedures and needle injections and for 30 minutes prior to minor dermatological procedures. www.synera.com. Pliaglis® is a topical local anesthetic cream that provides safe and effective local dermal anesthesia on intact skin prior to painful cosmetic procedures such as dermatologic laser surgery and dermal filler injections. This product consists of a proprietary formulation of lidocaine and tetracaine that utilizes our Peel technology. Pliaglis should be applied for 20-30 minutes prior to minor dermatological procedures, such as a dermal filler injections, and for 60 minutes prior to major dermatological procedures, such as laser-assisted tattoo removal. Following the application period, Pliaglis can easily be removed from the skin and the procedure can be performed. Pliaglis is approved by the FDA. Galderma owns the worldwide marketing rights to the product.